HUM

Business Context and Reporting Period

Company: Humana Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2006
Business Overview: Humana is a major health benefits company operating in two primary segments: Government (Medicare, TRICARE, Medicaid) and Commercial (employer groups, individuals). The reporting period reflects significant expansion into Medicare Part D prescription drug plans (PDP) and Medicare Advantage products, alongside a strategic acquisition of CHA Health in Kentucky.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 45.8% year-over-year, driven primarily by a 148% surge in Medicare premiums due to the launch of stand-alone Part D plans and growth in Medicare Advantage membership.
• Net Income Decline: Despite revenue growth, net income decreased 7.9% to $173.2 million. This was caused by higher medical costs associated with new PDP products, increased SG&A expenses for Medicare expansion, and a higher effective tax rate (36.2% vs. 22.1% in 2005, which included a one-time $22.8M tax gain resolution).
• Cash Flow Surge: Operating cash flow increased $1.27 billion. A significant portion ($1.03 billion) was due to the timing of Medicare premium receipts (July payments received in June) and enrollment growth.
• Segment Performance:
  • Government Segment: Income before taxes dropped 30.9% to $119.6 million due to high initial costs of new PDP plans.
  • Commercial Segment: Income before taxes rose 121.8% to $152.0 million, driven by improved medical expense ratios and the CHA Health acquisition.
• Debt Structure: Issued $500 million in 6.45% senior notes in May 2006. Repaid $200 million of credit agreement borrowings and $300 million of maturing senior notes (post-period).

Guidance, Outlook, and Risks

• Outlook: Management expects Government segment earnings to be considerably higher in the second half of 2006 as PDP medical expense ratios improve and SG&A leverage increases. Full-year 2006 Medicare premium revenues are expected to more than double 2005 levels.
• Expense Ratios: The consolidated SG&A expense ratio is projected to improve to 13-14% for the full year 2006. The effective tax rate is expected to range between 35% and 37%.
• Capital Expenditures: Expected to range between $155 million and $165 million for 2006, primarily for IT and infrastructure supporting Medicare expansion.
• Risks and Contingencies:
  • Government Contracts: Significant exposure to Medicare and TRICARE contracts; changes in reimbursement rates or legislative action could materially impact results.
  • Medical Cost Inflation: Rising healthcare costs and prescription drug utilization trends pose risks to margins.
  • Regulatory/Legal: Ongoing scrutiny by state and federal regulators regarding claims practices and potential litigation risks.
  • Accounting Changes: Adoption of SFAS 123R (stock-based compensation) and pending adoption of FIN 48 (uncertain tax positions) may impact future financial reporting.

Investor Verification Checklist

• Medicare PDP Margins: Verify the trajectory of Medical Expense Ratios (MER) for stand-alone PDP plans in subsequent quarters to confirm the expected improvement from the high initial costs seen in H1 2006.
• Commercial Membership Trends: Monitor the decline in fully insured commercial membership (down 6.3% YoY) to ensure pricing discipline and ASO growth continue to offset attrition.
• Debt Maturities: Confirm the successful repayment of the $300 million 7.25% senior notes maturing August 1, 2006, and the impact of the new $1 billion credit facility on liquidity.
• Tax Rate Normalization: Assess whether the effective tax rate stabilizes in the 35-37% range, excluding the one-time benefit recognized in the prior year.
• Acquisition Integration: Review the financial contribution of the CHA Health acquisition to the Commercial segment's profitability.